Ocuphire Pharma
preclinical enabling studies | Ocuphire Pharma
Company
Deck Type
Deck date
January 2022
Slide
15 of 114
Related slides by other companies
Freeman Capital Management
Activist
May 2023
preclinical safety studies | Freeman Capital Management
Arbutus Biopharma
Investor Presentation
May 2023
candidate | Arbutus Biopharma
AbCellera
Investor Presentation
November 2023
two led programs advancing into enabling studies | AbCellera
Avenue Therapeutics
IPO
October 2022
preclinical in studies demonstrate efficacy in multiple anxiety models | Avenue Therapeutics
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights